Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… lower mortality at 6 months, 1 year, and 3 years compared with alteplase, without increased intracerebral hemorrhage. Early cognitive im…
…ed RD and 95% CI, −2.1% (−8.5% to 4.4%), p=0.53). Compared with alteplase, DAPT was associated with lower risk of sICH (p=0.03) and bleed…
…unctional outcome, but functional outcomes were similar between Tenecteplase and alteplase overall.Conclusions We observed higher early repe…
…lase 36%, SAIL 58%; p<0.001) and fibrin-rich clots (plasma 22%, alteplase 38%, SAIL 51%; p<0.001).Conclusion The SAIL technique seems to …
…ural complexity. tenecteplase has pharmacologic advantages over alteplase, including greater fibrin specificity and longer half-life, whi…
…4) subgroups and in patients aged ≥90 years (n=160).Conclusions Tenecteplase and alteplase showed comparable efficacy and safety in patients…
…mRS 0–2 (OR: 1.41, 95% CI: 1.14 to 1.75, p=0.001) compared with alteplase.Conclusions Thrombolysis with TNK is not associated with an inc…
…hrombolysis, 8673 (median age (IQR), 84 (82–87) years) received alteplase treatment. Patients administered alteplase demonstrated improve…
…e and renal impairment complications, particularly for the drug tenecteplase. Therefore, we examined the association of impaired renal funct…
…3.0%). Tenecteplase recipients (n=252) had higher TM rates than alteplase recipients (19.4% vs 11.5%, adjusted OR (aOR) 1.83, 95% CI 1.10…
…d with greater early thrombus movement before EVT compared with alteplase. In this cohort thrombus movement category did not predict 90-d…
… thrombolytic administered within 4.5 hours of stroke symptoms. Tenecteplase (TNK) is FDA-approved for STEMI, but its off-label use for AIS …